37th Annual Pediatric Infectious Disease Update

Friday, April 14, 2023, 7:30 AM - Saturday, April 15, 2023, 1:00 PM CST, Big Cedar Lodge


The 37th Annual Pediatric Infectious Disease Update aims to provide education to anyone who provides care to pediatric patients on common infectious disease conundrums that arise, covering topics ranging from COVID to how to handle penicillin allergic patients to diagnosing monkeypox. This course consist of two half days of interactive discussions at Big Cedar Lodge near Branson, Missouri.

1. evaluate and treat patients with novel pathogens such as monkeypox, covid, histoplasmosis and blastomycosis.
2. plan the best empiric antibiotic regimens for individuals with STIs, UTIs, cervical lymphadenitis and penicillin allergies
3. be able to counsel patients on COVID vaccines and therapeutics and the nature of pandemics and what to expect in the future.

AMA PRA Category 1 Credits™ (8.75 hours), AAPA - American Academy of PAs Category 1 CME (8.75 hours), ACPE - Accreditation Council for Pharmacy Education (8.75 hours), ANCC - American Nurses Credentialing Center (8.75 hours), Non-Physician AMA PRA Category 1 Credits™ (8.75 hours)

In support of improving patient care, University of Arkansas for Medical Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

You are not logged in.

Please click the button below to login or create a new account before continuing.

Mitigation of Relevant Financial Relationships

University of Arkansas for Medical Sciences Office of Continuing Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.